Click image to enlarge
The R-PLEX platform offers both antibody sets and assays for a wide menu of biomarkers. The R-PLEX Human GFAP Assay has the essential components to build an assay that measures GFAP in a single analyte format. For information on multiplexing GFAP with other analytes, please see the
R-PLEX Assay Designer or the
R-PLEX Human GFAP Antibody Set.
The Product Insert for R-PLEX Assays provides detailed instructions for building a singleplex assay. The datasheet for GFAP provides information on the components (including calibrator stock concentration), recommended sample types and dilution factors, and representative data for analytical performance. These items and other helpful documents can be found in the "Documentation" tab below.
Related Key TermsGlial fibrillary acidic protein, ALXDRD, astrocytes, cytoskeleton structure, blood-brain barrier, Down's syndrome, depression, traumatic brain injury, neurodegeneration, stroke
-
-
Specifications
-
Kit Contents
-
Documentation
-
References
Application(s)
|
|
Neuroinflammation
,
Immunology/Inflammation
|
|
Analyte(s)
|
|
GFAP
|
|
Species
|
|
Human
|
|
Instrument(s)
|
|
SECTOR Imager 2400
,
SECTOR Imager 6000
,
MESO QuickPlex SQ 120
,
MESO QuickPlex SQ 120MM
,
MESO SECTOR S 600
,
MESO SECTOR S 600MM
|
|
Plate Type
|
|
96-well
|
|
LLOD (Sensitivity)
|
|
63 pg/mL
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
Storage Condition
|
|
Multi-Component
|
|
Gene ID(s)
|
|
2670
|
|
UniProt ID(s)
|
|
P14136
|
|
Schedule B Code
|
|
3822.19.0000
|
|
Product Description
|
Storage
|
Quantity per Kit
|
Human GFAP Antibody Set
|
2-8 °C
|
1 each (5 plate size)
|
|
Human GFAP Calibrator
|
≤-70 °C
|
5 vial (1 vial)
|
|
|
2-8 °C
|
5 each (1 plate)
|
|
|
2-8 °C
|
1 bottle (50 mL)
|
|
|
≤-10 °C
|
1 bottle (30 mL)
|
|
|
≤-10 °C
|
1 bottle (50 mL)
|
|
|
RT
|
1 bottle (90 mL)
|
|
Product Inserts
|
|
|
Datasheets
|
|
|
Handouts
|
|
|
SDS
|
|
|
Title
|
Journal
|
Year
|
|
Plasma biomarkers for diagnosis of Alzheimer’s disease and prediction of cognitive decline in individuals with mild cognitive impairment
|
|
|
|
Elevation of neural injury markers in patients with neurologic sequelae after hospitalization for SARS-CoV-2 infection
|
|
|
|
|
Order Details
Catalog No
Size
Price in USD
Qty
Meso Scale Japan 株式会社